These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30282116)

  • 1. The contribution of respiratory microbiome analysis to a treatable traits model of care.
    Taylor SL; O'Farrell HE; Simpson JL; Yang IA; Rogers GB
    Respirology; 2019 Jan; 24(1):19-28. PubMed ID: 30282116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting respiratory microbiomes in COPD and bronchiectasis.
    Mac Aogáin M; Tiew PY; Jaggi TK; Narayana JK; Singh S; Hansbro PM; Segal LN; Chotirmall SH
    Expert Rev Respir Med; 2024; 18(3-4):111-125. PubMed ID: 38743428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision medicine and treatable traits in chronic airway diseases - where do we stand?
    Ulrik CS; Vijverberg S; Hanania NA; Diamant Z
    Curr Opin Pulm Med; 2020 Jan; 26(1):33-39. PubMed ID: 31644440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of sputum microbiome studies identifies airway disease-specific taxonomic and functional signatures.
    Ghosh A; Saha S
    J Med Microbiol; 2022 Dec; 72(12):. PubMed ID: 36748565
    [No Abstract]   [Full Text] [Related]  

  • 5. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.
    Polverino E; Dimakou K; Hurst J; Martinez-Garcia MA; Miravitlles M; Paggiaro P; Shteinberg M; Aliberti S; Chalmers JD
    Eur Respir J; 2018 Sep; 52(3):. PubMed ID: 30049739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatable traits models of care.
    McDonald VM; Holland AE
    Respirology; 2024 Jan; 29(1):24-35. PubMed ID: 38087840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Composition of microorganism community in the airways of patients with chronic obstructive pulmonary disease].
    Fedosenko SV; Ogorodova LM; Freidin MB; Saltykova IV; Kulikov ES; Deev IA; Kirillova NA; Selivanova PA; Balasheva II
    Klin Med (Mosk); 2014; 92(8):26-32. PubMed ID: 25790693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiota abnormalities in inflammatory airway diseases - Potential for therapy.
    Gollwitzer ES; Marsland BJ
    Pharmacol Ther; 2014 Jan; 141(1):32-9. PubMed ID: 23969226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatable traits approach to adults with obstructive airways disease in primary and secondary care.
    Thomas M; Beasley R
    Respirology; 2023 Dec; 28(12):1101-1116. PubMed ID: 37877554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change is in the air: key questions on the 'Treatable Traits' model for chronic airway diseases in primary care.
    Agusti A; Gibson PG; Heaney LG; Thomas M
    NPJ Prim Care Respir Med; 2024 Jul; 34(1):21. PubMed ID: 39025870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatable traits of chronic airways disease.
    Fingleton J; Hardy J; Beasley R
    Curr Opin Pulm Med; 2018 Jan; 24(1):24-31. PubMed ID: 29049049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients.
    Millares L; Pascual S; Montón C; García-Núñez M; Lalmolda C; Faner R; Casadevall C; Setó L; Capilla S; Moreno A; Castro-Acosta AA; Alvarez-Martinez CJ; Sibila O; Peces-Barba G; Cosio BG; Agustí A; Gea J; Monsó E
    BMC Pulm Med; 2019 Jun; 19(1):112. PubMed ID: 31234826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The airway microbiome in COPD, bronchiectasis and bronchiectasis-COPD overlap.
    Tiew PY; Jaggi TK; Chan LLY; Chotirmall SH
    Clin Respir J; 2021 Feb; 15(2):123-133. PubMed ID: 33063421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lung microbiome and exacerbations of COPD.
    Dy R; Sethi S
    Curr Opin Pulm Med; 2016 May; 22(3):196-202. PubMed ID: 26964078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral-lung microbiome interactions in lung diseases.
    Mammen MJ; Scannapieco FA; Sethi S
    Periodontol 2000; 2020 Jun; 83(1):234-241. PubMed ID: 32385873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional effects of the microbiota in chronic respiratory disease.
    Budden KF; Shukla SD; Rehman SF; Bowerman KL; Keely S; Hugenholtz P; Armstrong-James DPH; Adcock IM; Chotirmall SH; Chung KF; Hansbro PM
    Lancet Respir Med; 2019 Oct; 7(10):907-920. PubMed ID: 30975495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The lung microbiome in 2015: a window on chronic lung diseases].
    Andréjak C; Delhaes L
    Med Sci (Paris); 2015 Nov; 31(11):971-8. PubMed ID: 26576604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
    Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
    Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lung Microbiome and Airway Disease.
    Lynch SV
    Ann Am Thorac Soc; 2016 Dec; 13 Suppl 2(Suppl 5):S462-S465. PubMed ID: 28005424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.
    Agusti A; Barnes N; Cruz AA; Gibson PG; Heaney LG; Inoue H; Leather D; Martinez FJ; McDonald VM; Oppenheimer J; Papi A; Pavord ID; Thomas M; Walker S; Yates L
    Respir Med; 2021 Oct; 187():106572. PubMed ID: 34478992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.